Heidelberg Pharma AG
Company Profile
Business description
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
Contact
Gregor-Mendel-Street 22
Ladenburg68526
DEUT: +49 620310090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 November 2026
Employees
66
Stocks News & Analysis
stocks
The ASX data center stock flying under the radar
stocks
What did Morningstar subscribers buy and sell during June?
stocks
Australia’s largest gold miner downgraded on a falling gold price
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,001.30 | 3.70 | 0.04% |
| CAC 40 | 8,366.85 | 2.20 | 0.03% |
| DAX 40 | 25,147.03 | 32.78 | 0.13% |
| Dow JONES (US) | 52,508.27 | 9.63 | 0.02% |
| FTSE 100 | 10,529.39 | 31.10 | 0.30% |
| HKSE | 24,340.73 | 127.01 | 0.52% |
| NASDAQ | 26,107.01 | 233.83 | 0.90% |
| Nikkei 225 | 67,743.50 | 500.77 | 0.74% |
| NZX 50 Index | 13,674.02 | 22.80 | 0.17% |
| S&P 500 | 7,543.59 | 28.25 | 0.38% |
| S&P/ASX 200 | 8,808.50 | 4.80 | 0.05% |
| SSE Composite Index | 3,967.13 | 53.33 | 1.36% |